Loading…
← CockpitCompetitor Analysis › SUPRIYA.NS Supriya Lifescience LimitedOpen in the cockpit ↗

Supriya Lifescience LimitedSUPRIYA.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major
Momentum laggard 3
Mkt cap
$529M
US dollars, full cap
Free float
29%
of shares outstanding
$/day
$3.38M
20-day average traded
Fwd P/E
36.2×
forward earnings
ROIC−WACC
+0.2 pp
WACC 14.4%
Hurdle
+12 pp
Req g minus delivered
Next earnings
90 days
16 Feb 2027
Close · INR₹614.80
1D-0.9%
1W-3.6%
1M-29.6%
3M-23.3%
6M-14.7%
YTD-18.2%
1Y-19.4%
ATR %5.8%
Beta0.50
52w lowhigh43.3% off high

What Supriya Lifescience does

Employees: 1,310

Supriya Lifescience at a glance

Size Supriya Lifescience (SUPRIYA.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $529M, the 829th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹614.80 on 18 Nov 2026.

Performance Over six months the shares fell 14.7%, against -15.9% for the median peer and +3.8% for the India market (cap-weighted) — 10th highest of 19 in its peer set.

Growth Revenue grew 23.0% over the last twelve months (peer median +6.7%); the operating margin is 26.0% (peer median 6.4%).

Valuation It trades at 36.2× forward earnings against a peer median of 11.3× (most expensive of 8).

Price implies For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 0.2 points above its cost of capital (14.4% WACC).

Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).

Relative performance

8010012014021 May 202621 Aug 202618 Nov 2026SUPRIYA.NS 85Peer median 84
Six months, rebased to 100: Supriya Lifescience against the median of its 20 peers (local-currency closes).

Supriya Lifescience financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹8.79B₹8.02B₹6.80B₹5.57B₹4.50B
Revenue growth—+18%+22%+24%—
Gross profit₹4.47B₹3.22B₹2.96B₹1.97B₹1.54B
EBITDA₹2.63B₹2.81B₹2.55B₹1.69B₹1.27B
Net income₹1.77B₹2.09B₹1.88B₹1.19B₹899M
Free cash flown/a₹430M₹102M-₹223M-₹358M
Capital expendituren/a₹1.52B₹1.62B₹1.46B₹1.08B
Total debt₹58.0M₹54.4M₹53.8M₹54.9M₹225M

Quarterly statements and history in the cockpit →

Supriya Lifescience competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%+150%-20%0%+20%000919603222SENORES300485MOREPENLABEGTX0026884559ZVRAINDP003850GUJTHEMGYRESUPRIYA.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Supriya Lifescience is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%+60%+80%10×20×30×SENORESEGTX0026884559ZVRA003850002393SUPRIYA.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Supriya Lifescience is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%000919EVONILE6036764559ZVRA003850002393SUPRIYA.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Supriya Lifescience is the large dot.

Supriya Lifescience competitors and peer comparison

How Supriya Lifescience compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Supriya Lifescience against its 20 peers (data as of 18 Nov 2026)
MeasureSUPRIYA.NSPeer medianRank in peer set
1-month return-29.6%-7.0%2nd lowest of 20
6-month return-14.7%-15.9%10th highest of 19
Distance from 52-week high-43.3%-38.7%7th lowest of 20
Revenue growth (TTM)+23.0%+6.7%5th highest of 19
Operating margin26.0%6.4%4th highest of 19
Forward P/E36.2×11.3×most expensive of 8
Growth the price implies (Req g, 7 yrs)28.2%-4.9%2nd most demanding of 10
Growth delivered (Del g)+15.8%+9.6%2nd highest of 10
Hurdle (Req g minus delivered)+12.4 pp-13.0 pp2nd most demanding of 10
ROIC minus cost of capital+0.2 pp-2.4 pp6th highest of 18
EV / EBITDA18.6×13.2×3rd most expensive of 7
Net debt / EBITDA-0.3×1.5×2nd least indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Supriya Lifescience SUPRIYA.NSIndia$529M-15%+23%26%36.2×28.2%+15.8%
Jinling Pharmaceutical 000919.SZChina$529M-15%-8%1%n/a2.4%+5.0%
Evonile Pharma EVONILE.NSIndia$529Mn/a-5%12%n/a49.3%-1.5%
Electra Therapeutics ETRAUnited States$530Mn/an/an/an/an/an/a
Chimin Health Management 603222.SSChina$533M-31%+1%-28%n/an/an/a
Senores Pharmaceuticals SENORES.NSIndia$538M+3%+40%24%32.2×n/an/a
Beijing Science Sun Pharmaceutical 300485.SZChina$517M-29%-11%-8%n/an/an/a
Morepen Laboratories MOREPENLAB.NSIndia$542M+121%+30%11%n/an/an/a
Xizang Weixinkang Pharmaceutical 603676.SSChina$513M-22%-8%16%n/a-6.1%+9.6%
Egetis Therapeutics EGTX.STSweden$509M+76%+27%-645%15.1×n/an/a
Jinhe Biotechnology 002688.SZChina$550M-19%+7%5%8.9×1.0%+9.7%
Zeria Pharmaceutical 4559.TJapan$552M-12%+12%15%9.6×-12.3%+11.1%
Zevra Therapeutics ZVRAUnited States$552M-9%+75%31%11.3×-4.9%+51.6%
Indaptus Therapeutics INDPUnited States$505M+147%n/an/an/an/an/a
Boryung 003850.KSSouth Korea$554M-13%+6%6%11.3×-3.1%+12.6%
Gujarat Themis Biosyn GUJTHEM.NSIndia$505M+2%+18%39%n/an/an/a
Aclaris Therapeutics ACRSUnited States$555M-23%-59%-1,412%n/an/an/a
Shanghai Xiao Fang Pharmaceutical 603207.SSChina$503M-17%+10%39%n/a-5.4%+7.6%
Tianjin Lisheng Pharmaceutical 002393.SZChina$557M-24%-3%7%9.0×-5.8%+4.1%
Gyre Therapeutics GYREUnited States$500M-28%+14%-18%n/an/an/a
Zhong Zhu Healthcare 600568.SSChina$562M-22%-6%-34%n/an/an/a

Questions

Which companies are Supriya Lifescience's closest peers?
The cockpit's peer set: Jinling Pharmaceutical (000919.SZ), Evonile Pharma (EVONILE.NS), Electra Therapeutics (ETRA), Chimin Health Management (603222.SS), Senores Pharmaceuticals (SENORES.NS), Beijing Science Sun Pharmaceutical (300485.SZ), Morepen Laboratories (MOREPENLAB.NS), Xizang Weixinkang Pharmaceutical (603676.SS).
Is Supriya Lifescience expensive compared with its peers?
On forward p/e it trades at 36.2× against a peer median of 11.3×, most expensive of 8 in its peer set. For today's price to make sense, revenue must grow about 28% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Supriya Lifescience stock performed?
Over six months to 18 Nov 2026 the shares returned -14.7% against -15.9% for the median peer; over one year -19.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.